{"ticker": {"uuid": "302271a5-8c0c-4907-b671-1010092470fa", "symbol": "RDHL", "name": "Redhill Biopharma Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Redhill Biopharma Ltd (RDHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a company overview for Redhill Biopharma Ltd (RDHL) focusing on revenue breakdown. However, it explicitly states that relevant data regarding business segments and regional revenue have not been disclosed by the company yet. The page displays current stock i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T21:40:06", "published_display": "18 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Redhill Biopharma Ltd's (RDHL) dividend and stock split history. It notes that the company has distributed no dividends over the past five years and lists several merger-related stock splits, including 25-to-1 splits scheduled for August 6, 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T21:40:06", "published_display": "18 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (RDHL) Secures $6M in Private Placement Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPMTVrVHV5MTJyWjdndUlRNXFNekpzVktCUUE4R1dTVmFPVjAxVENWSXVpVnc5cmxGaktNXzZaZ3pmR3Q4OGFiUmtJMl81YlVFUlZIa3ptVFBxSlRmMVRYeEZUNDdwVXU4N25KSlVqSTJYQVlQZ2hoSkZQU29TcWZVRzJLQlppX0FNQkpkdzFadG1tMWtSQkg0c2Joem02a1k?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T13:50:32+00:00", "published_display": "18 Jun 2026 13:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (Nasdaq: RDHL) prices $6M ADS private placement with warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQVENOMjFwd1otSFVqbUJlV1VibEcza2gxV1FGNnBEeFB5bWI2LTcwczk5SVFvNW1JbGJLZjc0aTdITW9jeTA5a0NRREtoY0tMVWZwb196aGdjeWFXXzg4REVSMDJENDFTVmxFS1pOZzNkeUhQa1Rab0VPTnFFQnFTa2thVVYxWVpwTHMyaTV1VDRzLUhIWURWSzQ2bDk1RVJMZDBzbXd4cVh5eDBzd1NSWGhCMi1sZUtUcUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:03:32+00:00", "published_display": "18 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma raises $6M now, with $13.4M more tied to warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTTBCNnFEZ0pGVkdhR3BvRG04eDZUd2FnMHBKMGQ4VUdYLTg1TXh1TmQ4NHJpc1BLWWRqMllDLUZ3ZzJ0Mk0wS1l5M05vTTMwaTRWemNmQWQ0QkpXcHBFNEEyeFRLWHdvR19xRG5XdlMyaWtQWDFTYlNoN1pzemN4R1ctbUF5bkpKRkxKQ05vaWhoMVptWEJpOWFKYmwzRnZWNzNRTHJ1aU5SM1V5cGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma raises $6M in private placement", "summary": "RedHill Biopharma Ltd. announced it has entered into a definitive agreement for a private placement expected to generate $6 million in gross proceeds. The company will sell 8,571,429 American Depositary Shares at $0.70 per ADS with accompanying warrants. The proceeds are intended", "url": "https://www.investing.com/news/company-news/redhill-biopharma-raises-6m-in-private-placement-93CH-4749845", "source_name": "Investing.com", "published_at": "2026-06-18T12:40:06", "published_display": "18 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma raises $6M in private placement By Investing.com", "summary": "RedHill Biopharma announced a definitive agreement for a private placement expected to generate $6 million in gross proceeds. The company will sell 8,571,429 American Depositary Shares at $0.70 per ADS, with accompanying warrants that could bring in an additional $13.4 million if", "url": "https://ca.investing.com/news/stock-market-news/redhill-biopharma-raises-6m-in-private-placement-93CH-4698238", "source_name": "Investing.com Canada", "published_at": "2026-06-18T12:39:40", "published_display": "18 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Announces Up To $19.4 Million Private Placement", "summary": "RedHill Biopharma announced a private placement totaling up to $19.4 million, comprising $6 million upfront from the sale of American Depositary Shares (ADSs) and accompanying warrants, with an additional potential $13.4 million from the full exercise of these warrants. The funds", "url": "https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html", "source_name": "PR Newswire", "published_at": "2026-06-18T11:39:40", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast analysis for Redhill Biopharma Ltd (RDHL), noting that no specific earnings forecast score is currently available, contrasting with the pharmaceuticals industry average of 7.84. It highlights the company's current stock performance, mark", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:41", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Redhill Biopharma Ltd (RDHL), detailing its current price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of June 17, 2026, the stock has a price momentum score of 2.32, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/technical", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:40", "published_display": "17 Jun 2026 23:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE43R2E3MURaYnIxdW1jaDluQ0daZVgwckhDaWdnMVpRcnNzTjVyZVVZVWdCODhFNHIwdWR0c0ZJVWhRYnhkcnZYcTZSX0hvWGlhWjlQMnBSSElESWkwdU5nSjFJelpub1drbmpaY2lEMDBYWUhkb01EUUpn?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Valuation: PE, PB & Fair Value Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFA1cHZpVkVLbE40RUtjU0E4UmZOZllFdWE5aEg1S0Z2dUNFanE1Z18zN0prcmt1NmVMS0lsLUtzR1BxdEZIeWt6VW9zSjFtQTRuZWZWR21OeWI5eV80bmtSdUhQRmdyQnI3NktMcllzMTNjQlF4UGJrc1djMA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE8tV1Y1ekpOdzdxeWVWUTJGclBmRndBUkM0NUEwUU00SzNWbjJlSFRtWHdDNU5DcHAzSkpNeWVzUUpxSGtZZ2V1TEZfaTRYSEVBY3FKSzJqZC1oYk0xcmktSGE4STRadm9fTEg5MEptY1pqT0d6WWVV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo", "summary": "RedHill Biopharma Ltd. announced it has started recognition and enforcement proceedings in Korea for an $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd. The judgment, which became final in November 2025 for the principal award, and in March 2026 for legal fees", "url": "https://www.sahmcapital.com/news/content/redhill-launches-enforcement-of-11-million-new-york-supreme-court-final-judgment-against-kukbo-2026-06-08", "source_name": "Sahm", "published_at": "2026-06-11T23:39:41", "published_display": "11 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants rare pediatric disease status to RedHill (RDHL) drug opaganib", "summary": "RedHill Biopharma announced that its investigational drug opaganib received rare pediatric disease designation from the FDA for treating neuroblastoma, a cancer affecting children. This designation, in addition to existing orphan drug status, makes opaganib eligible for benefits ", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-37e82b459e94.html", "source_name": "Stock Titan", "published_at": "2026-06-10T09:09:57", "published_display": "10 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation", "summary": "RedHill Biopharma announced that its drug opaganib has received Rare Pediatric Disease (RPD) designation from the FDA for the treatment of neuroblastoma, a type of cancer affecting babies and young children. This designation, in addition to its existing Orphan Drug designation, o", "url": "https://www.yourwyominglink.com/redhills-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan/article_ac55bb16-cbc9-502a-8751-325377102f38.html", "source_name": "Your Wyoming Link", "published_at": "2026-06-10T08:40:53", "published_display": "10 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma opaganib wins FDA rare pediatric disease status", "summary": "RedHill Biopharma received Rare Pediatric Disease designation from the FDA for its drug opaganib, intended to treat neuroblastoma, a childhood cancer. This designation, alongside an existing orphan drug status, makes the company eligible for a Priority Review Voucher upon approva", "url": "https://grafa.com/en/news/united-states/redhill-biopharma-rdhl-fda-rare-pediatric-disease-designation", "source_name": "grafa.com", "published_at": "2026-06-09T12:05:00", "published_display": "09 Jun 2026 12:05", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (Nasdaq: RDHL) enforces $10.9M final judgment against Kukbo", "summary": "RedHill Biopharma (Nasdaq: RDHL) has initiated legal proceedings in Korea to enforce a $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd. This judgment includes a main award of $8.9 million and $1.95 million for legal fees, both accruing 9% statutory interest an", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-153e2495e99c.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:40:44", "published_display": "08 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma begins Korea enforcement of $10.9M judgment", "summary": "RedHill Biopharma has initiated proceedings in Korea to enforce a New York Supreme Court judgment against Kukbo Co. Ltd for approximately $10.9 million. The judgment, which includes principal, legal fees, and accrued interest, became eligible for enforcement after Kukbo failed to", "url": "https://www.investing.com/news/company-news/redhill-biopharma-begins-korea-enforcement-of-109m-judgment-93CH-4730359", "source_name": "Investing.com", "published_at": "2026-06-08T20:10:03", "published_display": "08 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma commences enforcement of $10.9M judgment against Kukbo", "summary": "RedHill Biopharma has initiated enforcement proceedings in South Korea to collect a $10.9 million judgment against Kukbo. This judgment, which includes an $8.9 million principal and $1.95 million in legal fees with 9% interest, stems from a breach of contract dispute. The New Yor", "url": "https://grafa.com/en/news/united-states/redhill-biopharma-enforces-kukbo-judgment", "source_name": "grafa.com", "published_at": "2026-06-08T15:10:51", "published_display": "08 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma begins Korea enforcement of $10.9M judgment By Investing.com", "summary": "RedHill Biopharma has initiated recognition and enforcement proceedings in Korea for a New York Supreme Court judgment against Kukbo Co. Ltd, totaling approximately $10.9 million. The judgment includes $8.9 million in principal and $1.95 million in legal fees and expenses, with a", "url": "https://za.investing.com/news/stock-market-news/redhill-biopharma-begins-korea-enforcement-of-109m-judgment-93CH-4317685", "source_name": "Investing.com South Africa", "published_at": "2026-06-08T11:10:51", "published_display": "08 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RDHL News | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE0tWHNXek5IaHRJSGN0dDdfeExHS3pVOFdzYXFtaldhV05GT1ZPM1Q4STlzUHZmTEpjLWxjMmFpOWJXRHNvYXVPTzNJOUV3MS1xY1RPQk1UejE3bEU?oc=5", "source_name": "ChartMill", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | Corporate", "summary": "RedHill Biopharma is actively pursuing collaborations, including with the WHO, to advance its investigational oral drug opaganib for an emerging Ebola virus disease (EVD) outbreak. Opaganib, which has demonstrated antiviral activity in severe COVID-19 and preclinical EVD studies,", "url": "https://www.eqs-news.com/news/corporate/redhill-biopharma-advancing-opaganib-options-for-ebola-virus-disease-outbreak/c8101217-7106-4dd1-a082-a1cd02f35d25_en", "source_name": "EQS News", "published_at": "2026-06-03T20:40:44", "published_display": "03 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak", "summary": "RedHill Biopharma is actively pursuing collaborations to advance its investigational oral drug, opaganib, for the treatment of Ebola Virus Disease (EVD), particularly in response to the Bundibugyo ebolavirus outbreak which lacks approved treatments. The company is in discussions ", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/redhill-biopharma-ltd/69478526", "source_name": "AD HOC NEWS", "published_at": "2026-06-03T16:10:38", "published_display": "03 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental Ebola pill opaganib in WHO CORE trial talks", "summary": "RedHill Biopharma is actively seeking collaborations, including with the WHO SOLIDARITY CORE platform, to evaluate its investigational drug opaganib as a potential treatment for the Bundibugyo ebolavirus subtype. The company highlights opaganib's Phase 3 severe COVID-19 data show", "url": "https://www.stocktitan.net/news/CPIX/red-hill-biopharma-advancing-opaganib-options-for-novel-dual-host-oywnhe4tg2wc.html", "source_name": "Stock Titan", "published_at": "2026-06-03T05:39:39", "published_display": "03 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (RDHL) pursues collaborations to test opaganib in Ebola", "summary": "RedHill Biopharma is actively seeking collaborations to advance its investigational oral drug, opaganib, for treating Ebola virus disease, especially given the current outbreak of the rare Bundibugyo ebolavirus sub-type. The company is in discussions with the World Health Organiz", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-7a11f6ebad04.html", "source_name": "Stock Titan", "published_at": "2026-06-03T05:39:38", "published_display": "03 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms", "summary": "RedHill Biopharma is actively discussing the clinical advancement of its investigational oral drug, opaganib, for Ebola virus disease (EVD), especially given a rapidly evolving outbreak of the rare Bundibugyo ebolavirus sub-type for which no approved medications exist. Opaganib a", "url": "https://www.sahmcapital.com/news/content/redhill-biopharma-advancing-opaganib-options-for-novel-dual-host-directed-and-direct-acting-antiviral-approach-for-ebola-outbreak-biodefense-platforms-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-02T19:10:51", "published_display": "02 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (RDHL) boosts capacity of at-the-market ADS program", "summary": "RedHill Biopharma has filed a prospectus supplement to increase the maximum aggregate offering amount of its at-the-market (ATM) American Depositary Shares (ADS) program. This program allows the company to issue and sell ADSs, each representing 10,000 ordinary shares, through H.C", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-98995b5012c3.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:09:19", "published_display": "27 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma (RDHL) Holds Steady at $1.01 as Key Levels Define Trading Range - Analyst Downgrade Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSm5valpKZUZjNTRSZVk2c3dpRUxmdGRxajVoTUx4c1k2TDAzWTFxblVuQ19DcEltRXFtTF8yWG1Oem1KVXVEZF9QaXlhMVQwQWEzaDBNV0NaQWVabmo5U1I4QnBHNDRiZERzMHFFNTd0bnZfeGhOVkNtQVNFbWVwQUVRMmRaZUY2Y0w0ZS1aeTcyN3RvYkFIWUg5THI4SXNIeklFYUtrR241UlJFcEQyVGtnVWoyOGhnZkE?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RDHL SEC Filings - Redhill Biopharm 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for Redhill Biopharma (RDHL), including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Recent filings discuss positive FDA feedback on RHB-204 for Crohn's disease, an equity line of credit for up to $10 mill", "url": "https://www.stocktitan.net/sec-filings/RDHL/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-11T22:12:19", "published_display": "11 May 2026 22:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] RedHill Biopharma Ltd. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVWJ1YkhHVm1hUWViMXZYU3BNSm8tbW1SVWUta2cxUEFvT0h2UEMtWkhJeUtnTXpDSDNGOElEckJKNFdKTFU3NnV0UDBhRUY0MC1jT0hyN3llNHRnT2xxdlRaSVBBWGpsN3ZBcHN3SDY4enA5T0dDcXl2VzVjbnFuTFdNU3ZLZXJMdUxENE95akF6SGRQTExnSWFWX0JqRGh2OUhZLQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxPOHgwM0lxd21EaUZPdUJLTmItdGlRZUhhZTZFbVlXSDk2Z0ptZEJVcTRveERLalhmbjRzT1JXaVg2d01YWmxIVFYxNHhvMm1ZVDk3NlNIYWtpa0xUR2hJYTlvYXpZc0x6TklaeUVzVjVtT2NfaGZDN2RQdFgwekppbDRsNUU2NWdqRHAyZElaMWR4YXUwSWhsVXRNM0ZjaUp6bDV0TW9rUU5LQW9ka0Nyb1dzOVZoVXZLRVB0Z3J5LWU3VVJmR0FWZk1ZT2dqdnBGZWloVTZnMWRtTXAyQXU2MEt4LWdvaVppWUV1MG5nWUt4SUxuQnJlVjBrTEgyRnRvRXh3Q2RUOHloNWZ5Yy1KVnhkZDR3OGdRNXFnVWtucjR3cVhSQVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPNVN5VWRHWmdvT0ZNYUpzN2l2dmc4WDFMSVpuQTJub1JKNC12Z0hBLUtoMVhVZkN6bEFCQ0lQZEhxMEFuTDc1TlFCRHJmTTBiTFNyV3VyZUR6VGxybUNXN1phRURTeU04d2pLZUt2eE5KNVJOMVNhVFhwVm9ReXF4endXbVp4bDBGZ1Q2dElxMi0yeVRXWkc2VVV2OGpUNVhLaXluWDZzclAweVdGUVVNd3pWaW1RY1VzTlBsc2gxd3RheFFtNmI5Q05FY01qVEtCYzcxczI4OWYwNmJycHVv?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Joint U.S. Commercialization of RedHill's Talicia\u00ae Commences", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOUzZOaDZKQTFSQktQR3QtTTdXTUZ2S1lkcWs1ZXhJZFh1QlpzazB6ck5VRGJfRVFQdTBtLWNiMTNxbWsyNzI2aVdHX25tMGFkREJrNmU5S2NvQUxJUkRRYmRWa180SUs4X3lSdDlaMlY3NHBZZmpCRk51TG5VQXdJMl9tX255RWNEYlkzWlVRQkRTZFN1RnJsemZ2MTRMRzUtSW9UR3dfdl85TkxBb2JnUnhB?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma stock soars on GLP-1 side effect treatment progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQUHl6anU4c0ZZN3FwZThtWURlT1h5ajI1am44c0NxOFpZbWRrRUVCelU4dGQ5Q0lvd1p6UkFkVlpQRkJwXzFvU3U0RWxRcG5QVVBtUnJuR25wMHRZS1g3V0dVWDhvenV2TURpdlFtamh4RzRuQ2xfekxMaXBudUExcjhvbnhnQ0t2N3hxMnVva0VoRmtXTG11VVlBZGh2MzUtR01sUlNwa2RRVFNVNVpfWUR3S0prMmk3NERzVnVwV183T0tUNzR6Rmxn?oc=5", "source_name": "Investing.com", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPcy1Oa25uZGRxd2JJNlRDaTllbnlZdUYyTjBPWXpRV01ETmVLbzJaM2QybWhDeWhtdDcwaC0xZTlqSmx0ZFZwZ1Fhbk0yM0p3aHVRSTVaWHFZM2RZU0MzRFBVaHc2V2E4ck5HY1lLX0R3aGNIbjZSLXNFVDB4NmN0TUlNbndIZUdOTkJWQ1JCX3RvVWttWVNHZ292RGxRclRvTjFrb3ZodHMxOFBYX29KdU5sdWpHcXhKbHJpZzhWTkkybmZLclh1eUF1Z3lBV1c5OUlVbGdYdGZkT2FBa3Bmc3l3NA?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's $1.8M Middle East Deal Signals Global Demand for Effective H. pylori Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNDFFSms4TkhWeTFHZTh0eHpxRlR3d2hTazFCV2J2Wi0teDVJQ01LVTViekNRTlRSMjc3b3NBSEVyMThYUTJieFBxcFcza3ZxM09Dam5MTFJXSzVyWVFOdjNnNldfejB4X00tc241WFhudkc5VW9TZEg4UE5iZzdhaWJCampIWGZtN3c0ZUQ0RUtaYWhvMzRiRXdOd1lxaENxaXhOUmxBX3dROVQwSVZlaG1odDUxajRO?oc=5", "source_name": "PharmTech.com", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOTHZ5ZzY1Skx2dXVRWTBmczRWaXpteU9nV0ZYd2xKRGJ3aXNGOUI3elZIR0xfRjdlcGIzVTk0cXBxTXlDRWhLUzNBd2E2SFlxejFuWDdpYXUxdE11MmJLSHQtSXpZc3ZKQ3VQTHdkaXdnc2JNZVZGQThyYzl6RVlHR1Jtal8xdmVZZXhQaUJBUmhBeVlWckczYUNQMGJiYmEyZzNNSVo1YTEzMUtxRTZGLVN4X25MOFJMRVVHaU9yWE5RNjM0QXBMd3VmdTBMYkRTZ2tZWW5fdHRTV2lXYllQSw?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-05T07:00:00+00:00", "published_display": "05 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOUEhDczdxWjZTYTBwYXZxaEtwVWdFdG1YWkZ1NDFqOWpkLU9JcEl1UmZDSFhib3F2Y05SbmlWTGY3djV0MFNQeUwwenV0MjdDdjNnQkZaMUJsVHB1MERNV2JWdEFiU19CX2hyVWpXRnhMQzNNS1BkZXA4N3h0TzlMYkhZUVF2dV9wWGhUWTQxQ3VDUE9Ea1ZXOURqLXA1U0p6Yk5ST19YVlF2ZzZxTlo2d2Z0YzdUTUNsQW5XUXA3MFhENnVOMHlTWkFubDlVSWdWYlFwTmtlZEpuQk8yNldlakF0bEYtXzlVMGRuejBR?oc=5", "source_name": "PR Newswire", "published_at": "2024-10-14T07:00:00+00:00", "published_display": "14 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's Talicia\u00ae Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdXpoLVE3VWR0SVk1X0tfRkZ1RTFvckR0YjlsYm1XUjBHRll4ekVsSVJubFYxU05TSm40R1lzMWcxa203Vzg1LXBudmhKT3J1VFFxVlBKNjBLVDBYSjRmTG4ycWJPSGhvZnpzWm95QjVBTEotbWlxaGlzakdDdUp4Zjh5SW5OZjRCRndqSWVwODF2eUFCbnlEbDJ4bkZoaG41cHRxYVZfbzZuRWRzZk9lNzBjb2lkM0hzWXBwcW5uTE4?oc=5", "source_name": "Stock Titan", "published_at": "2024-09-09T07:00:00+00:00", "published_display": "09 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Redhill Biopharma (RDHL) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOeldnLURLZDg0YVJRWGlYdUJRYWFYanQ3YnBUOS1mTktnM1o4bGxVOFQyUThwamJycnZTS0gyMnhtMHpFd29hQ2Q2NE80cTNvU21KUUx1RUxPbmxCaF9TandHbGRoUEVfVDhjaXc4NVlKNWJPZ2cxa3kza0xJLWVsQw?oc=5", "source_name": "MarketBeat", "published_at": "2020-04-30T03:00:09+00:00", "published_display": "30 Apr 2020 03:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RDHL Stock Price and Chart \u2014 NASDAQ:RDHL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5QOGctMGxneEZxZzhlblctX0ZoUlN2UlJwazE4cVBhc2R0T0liUFpRWkYxRll2UzBkMHBRdC04bXFQZHd0TXFFMGh0RFFiaVVjb095Mnc3MGExb1Z0?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:06:25+00:00", "published_display": "21 Jul 2017 03:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Redhill Biopharma Ltd (RDHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a company overview for Redhill Biopharma Ltd (RDHL) focusing on revenue breakdown. However, it explicitly states that relevant data regarding business segments and regional revenue have not been disclosed by the company yet. The page displays current stock i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T21:40:06", "published_display": "18 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Redhill Biopharma Ltd's (RDHL) dividend and stock split history. It notes that the company has distributed no dividends over the past five years and lists several merger-related stock splits, including 25-to-1 splits scheduled for August 6, 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T21:40:06", "published_display": "18 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (RDHL) Secures $6M in Private Placement Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPMTVrVHV5MTJyWjdndUlRNXFNekpzVktCUUE4R1dTVmFPVjAxVENWSXVpVnc5cmxGaktNXzZaZ3pmR3Q4OGFiUmtJMl81YlVFUlZIa3ptVFBxSlRmMVRYeEZUNDdwVXU4N25KSlVqSTJYQVlQZ2hoSkZQU29TcWZVRzJLQlppX0FNQkpkdzFadG1tMWtSQkg0c2Joem02a1k?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T13:50:32+00:00", "published_display": "18 Jun 2026 13:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (Nasdaq: RDHL) prices $6M ADS private placement with warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQVENOMjFwd1otSFVqbUJlV1VibEcza2gxV1FGNnBEeFB5bWI2LTcwczk5SVFvNW1JbGJLZjc0aTdITW9jeTA5a0NRREtoY0tMVWZwb196aGdjeWFXXzg4REVSMDJENDFTVmxFS1pOZzNkeUhQa1Rab0VPTnFFQnFTa2thVVYxWVpwTHMyaTV1VDRzLUhIWURWSzQ2bDk1RVJMZDBzbXd4cVh5eDBzd1NSWGhCMi1sZUtUcUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:03:32+00:00", "published_display": "18 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma raises $6M now, with $13.4M more tied to warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTTBCNnFEZ0pGVkdhR3BvRG04eDZUd2FnMHBKMGQ4VUdYLTg1TXh1TmQ4NHJpc1BLWWRqMllDLUZ3ZzJ0Mk0wS1l5M05vTTMwaTRWemNmQWQ0QkpXcHBFNEEyeFRLWHdvR19xRG5XdlMyaWtQWDFTYlNoN1pzemN4R1ctbUF5bkpKRkxKQ05vaWhoMVptWEJpOWFKYmwzRnZWNzNRTHJ1aU5SM1V5cGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma raises $6M in private placement", "summary": "RedHill Biopharma Ltd. announced it has entered into a definitive agreement for a private placement expected to generate $6 million in gross proceeds. The company will sell 8,571,429 American Depositary Shares at $0.70 per ADS with accompanying warrants. The proceeds are intended", "url": "https://www.investing.com/news/company-news/redhill-biopharma-raises-6m-in-private-placement-93CH-4749845", "source_name": "Investing.com", "published_at": "2026-06-18T12:40:06", "published_display": "18 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma raises $6M in private placement By Investing.com", "summary": "RedHill Biopharma announced a definitive agreement for a private placement expected to generate $6 million in gross proceeds. The company will sell 8,571,429 American Depositary Shares at $0.70 per ADS, with accompanying warrants that could bring in an additional $13.4 million if", "url": "https://ca.investing.com/news/stock-market-news/redhill-biopharma-raises-6m-in-private-placement-93CH-4698238", "source_name": "Investing.com Canada", "published_at": "2026-06-18T12:39:40", "published_display": "18 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Announces Up To $19.4 Million Private Placement", "summary": "RedHill Biopharma announced a private placement totaling up to $19.4 million, comprising $6 million upfront from the sale of American Depositary Shares (ADSs) and accompanying warrants, with an additional potential $13.4 million from the full exercise of these warrants. The funds", "url": "https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html", "source_name": "PR Newswire", "published_at": "2026-06-18T11:39:40", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast analysis for Redhill Biopharma Ltd (RDHL), noting that no specific earnings forecast score is currently available, contrasting with the pharmaceuticals industry average of 7.84. It highlights the company's current stock performance, mark", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:41", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Redhill Biopharma Ltd (RDHL), detailing its current price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of June 17, 2026, the stock has a price momentum score of 2.32, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rdhl/technical", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:40", "published_display": "17 Jun 2026 23:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE43R2E3MURaYnIxdW1jaDluQ0daZVgwckhDaWdnMVpRcnNzTjVyZVVZVWdCODhFNHIwdWR0c0ZJVWhRYnhkcnZYcTZSX0hvWGlhWjlQMnBSSElESWkwdU5nSjFJelpub1drbmpaY2lEMDBYWUhkb01EUUpn?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Valuation: PE, PB & Fair Value Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFA1cHZpVkVLbE40RUtjU0E4UmZOZllFdWE5aEg1S0Z2dUNFanE1Z18zN0prcmt1NmVMS0lsLUtzR1BxdEZIeWt6VW9zSjFtQTRuZWZWR21OeWI5eV80bmtSdUhQRmdyQnI3NktMcllzMTNjQlF4UGJrc1djMA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma Ltd (RDHL) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE8tV1Y1ekpOdzdxeWVWUTJGclBmRndBUkM0NUEwUU00SzNWbjJlSFRtWHdDNU5DcHAzSkpNeWVzUUpxSGtZZ2V1TEZfaTRYSEVBY3FKSzJqZC1oYk0xcmktSGE4STRadm9fTEg5MEptY1pqT0d6WWVV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo", "summary": "RedHill Biopharma Ltd. announced it has started recognition and enforcement proceedings in Korea for an $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd. The judgment, which became final in November 2025 for the principal award, and in March 2026 for legal fees", "url": "https://www.sahmcapital.com/news/content/redhill-launches-enforcement-of-11-million-new-york-supreme-court-final-judgment-against-kukbo-2026-06-08", "source_name": "Sahm", "published_at": "2026-06-11T23:39:41", "published_display": "11 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants rare pediatric disease status to RedHill (RDHL) drug opaganib", "summary": "RedHill Biopharma announced that its investigational drug opaganib received rare pediatric disease designation from the FDA for treating neuroblastoma, a cancer affecting children. This designation, in addition to existing orphan drug status, makes opaganib eligible for benefits ", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-37e82b459e94.html", "source_name": "Stock Titan", "published_at": "2026-06-10T09:09:57", "published_display": "10 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation", "summary": "RedHill Biopharma announced that its drug opaganib has received Rare Pediatric Disease (RPD) designation from the FDA for the treatment of neuroblastoma, a type of cancer affecting babies and young children. This designation, in addition to its existing Orphan Drug designation, o", "url": "https://www.yourwyominglink.com/redhills-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan/article_ac55bb16-cbc9-502a-8751-325377102f38.html", "source_name": "Your Wyoming Link", "published_at": "2026-06-10T08:40:53", "published_display": "10 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma opaganib wins FDA rare pediatric disease status", "summary": "RedHill Biopharma received Rare Pediatric Disease designation from the FDA for its drug opaganib, intended to treat neuroblastoma, a childhood cancer. This designation, alongside an existing orphan drug status, makes the company eligible for a Priority Review Voucher upon approva", "url": "https://grafa.com/en/news/united-states/redhill-biopharma-rdhl-fda-rare-pediatric-disease-designation", "source_name": "grafa.com", "published_at": "2026-06-09T12:05:00", "published_display": "09 Jun 2026 12:05", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (Nasdaq: RDHL) enforces $10.9M final judgment against Kukbo", "summary": "RedHill Biopharma (Nasdaq: RDHL) has initiated legal proceedings in Korea to enforce a $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd. This judgment includes a main award of $8.9 million and $1.95 million for legal fees, both accruing 9% statutory interest an", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-153e2495e99c.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:40:44", "published_display": "08 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma begins Korea enforcement of $10.9M judgment", "summary": "RedHill Biopharma has initiated proceedings in Korea to enforce a New York Supreme Court judgment against Kukbo Co. Ltd for approximately $10.9 million. The judgment, which includes principal, legal fees, and accrued interest, became eligible for enforcement after Kukbo failed to", "url": "https://www.investing.com/news/company-news/redhill-biopharma-begins-korea-enforcement-of-109m-judgment-93CH-4730359", "source_name": "Investing.com", "published_at": "2026-06-08T20:10:03", "published_display": "08 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma commences enforcement of $10.9M judgment against Kukbo", "summary": "RedHill Biopharma has initiated enforcement proceedings in South Korea to collect a $10.9 million judgment against Kukbo. This judgment, which includes an $8.9 million principal and $1.95 million in legal fees with 9% interest, stems from a breach of contract dispute. The New Yor", "url": "https://grafa.com/en/news/united-states/redhill-biopharma-enforces-kukbo-judgment", "source_name": "grafa.com", "published_at": "2026-06-08T15:10:51", "published_display": "08 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma begins Korea enforcement of $10.9M judgment By Investing.com", "summary": "RedHill Biopharma has initiated recognition and enforcement proceedings in Korea for a New York Supreme Court judgment against Kukbo Co. Ltd, totaling approximately $10.9 million. The judgment includes $8.9 million in principal and $1.95 million in legal fees and expenses, with a", "url": "https://za.investing.com/news/stock-market-news/redhill-biopharma-begins-korea-enforcement-of-109m-judgment-93CH-4317685", "source_name": "Investing.com South Africa", "published_at": "2026-06-08T11:10:51", "published_display": "08 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RDHL News | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE0tWHNXek5IaHRJSGN0dDdfeExHS3pVOFdzYXFtaldhV05GT1ZPM1Q4STlzUHZmTEpjLWxjMmFpOWJXRHNvYXVPTzNJOUV3MS1xY1RPQk1UejE3bEU?oc=5", "source_name": "ChartMill", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | Corporate", "summary": "RedHill Biopharma is actively pursuing collaborations, including with the WHO, to advance its investigational oral drug opaganib for an emerging Ebola virus disease (EVD) outbreak. Opaganib, which has demonstrated antiviral activity in severe COVID-19 and preclinical EVD studies,", "url": "https://www.eqs-news.com/news/corporate/redhill-biopharma-advancing-opaganib-options-for-ebola-virus-disease-outbreak/c8101217-7106-4dd1-a082-a1cd02f35d25_en", "source_name": "EQS News", "published_at": "2026-06-03T20:40:44", "published_display": "03 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak", "summary": "RedHill Biopharma is actively pursuing collaborations to advance its investigational oral drug, opaganib, for the treatment of Ebola Virus Disease (EVD), particularly in response to the Bundibugyo ebolavirus outbreak which lacks approved treatments. The company is in discussions ", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/redhill-biopharma-ltd/69478526", "source_name": "AD HOC NEWS", "published_at": "2026-06-03T16:10:38", "published_display": "03 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental Ebola pill opaganib in WHO CORE trial talks", "summary": "RedHill Biopharma is actively seeking collaborations, including with the WHO SOLIDARITY CORE platform, to evaluate its investigational drug opaganib as a potential treatment for the Bundibugyo ebolavirus subtype. The company highlights opaganib's Phase 3 severe COVID-19 data show", "url": "https://www.stocktitan.net/news/CPIX/red-hill-biopharma-advancing-opaganib-options-for-novel-dual-host-oywnhe4tg2wc.html", "source_name": "Stock Titan", "published_at": "2026-06-03T05:39:39", "published_display": "03 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (RDHL) pursues collaborations to test opaganib in Ebola", "summary": "RedHill Biopharma is actively seeking collaborations to advance its investigational oral drug, opaganib, for treating Ebola virus disease, especially given the current outbreak of the rare Bundibugyo ebolavirus sub-type. The company is in discussions with the World Health Organiz", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-7a11f6ebad04.html", "source_name": "Stock Titan", "published_at": "2026-06-03T05:39:38", "published_display": "03 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms", "summary": "RedHill Biopharma is actively discussing the clinical advancement of its investigational oral drug, opaganib, for Ebola virus disease (EVD), especially given a rapidly evolving outbreak of the rare Bundibugyo ebolavirus sub-type for which no approved medications exist. Opaganib a", "url": "https://www.sahmcapital.com/news/content/redhill-biopharma-advancing-opaganib-options-for-novel-dual-host-directed-and-direct-acting-antiviral-approach-for-ebola-outbreak-biodefense-platforms-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-02T19:10:51", "published_display": "02 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma (RDHL) boosts capacity of at-the-market ADS program", "summary": "RedHill Biopharma has filed a prospectus supplement to increase the maximum aggregate offering amount of its at-the-market (ATM) American Depositary Shares (ADS) program. This program allows the company to issue and sell ADSs, each representing 10,000 ordinary shares, through H.C", "url": "https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-98995b5012c3.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:09:19", "published_display": "27 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma (RDHL) Holds Steady at $1.01 as Key Levels Define Trading Range - Analyst Downgrade Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSm5valpKZUZjNTRSZVk2c3dpRUxmdGRxajVoTUx4c1k2TDAzWTFxblVuQ19DcEltRXFtTF8yWG1Oem1KVXVEZF9QaXlhMVQwQWEzaDBNV0NaQWVabmo5U1I4QnBHNDRiZERzMHFFNTd0bnZfeGhOVkNtQVNFbWVwQUVRMmRaZUY2Y0w0ZS1aeTcyN3RvYkFIWUg5THI4SXNIeklFYUtrR241UlJFcEQyVGtnVWoyOGhnZkE?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RDHL SEC Filings - Redhill Biopharm 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for Redhill Biopharma (RDHL), including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Recent filings discuss positive FDA feedback on RHB-204 for Crohn's disease, an equity line of credit for up to $10 mill", "url": "https://www.stocktitan.net/sec-filings/RDHL/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-11T22:12:19", "published_display": "11 May 2026 22:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] RedHill Biopharma Ltd. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVWJ1YkhHVm1hUWViMXZYU3BNSm8tbW1SVWUta2cxUEFvT0h2UEMtWkhJeUtnTXpDSDNGOElEckJKNFdKTFU3NnV0UDBhRUY0MC1jT0hyN3llNHRnT2xxdlRaSVBBWGpsN3ZBcHN3SDY4enA5T0dDcXl2VzVjbnFuTFdNU3ZLZXJMdUxENE95akF6SGRQTExnSWFWX0JqRGh2OUhZLQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxPOHgwM0lxd21EaUZPdUJLTmItdGlRZUhhZTZFbVlXSDk2Z0ptZEJVcTRveERLalhmbjRzT1JXaVg2d01YWmxIVFYxNHhvMm1ZVDk3NlNIYWtpa0xUR2hJYTlvYXpZc0x6TklaeUVzVjVtT2NfaGZDN2RQdFgwekppbDRsNUU2NWdqRHAyZElaMWR4YXUwSWhsVXRNM0ZjaUp6bDV0TW9rUU5LQW9ka0Nyb1dzOVZoVXZLRVB0Z3J5LWU3VVJmR0FWZk1ZT2dqdnBGZWloVTZnMWRtTXAyQXU2MEt4LWdvaVppWUV1MG5nWUt4SUxuQnJlVjBrTEgyRnRvRXh3Q2RUOHloNWZ5Yy1KVnhkZDR3OGdRNXFnVWtucjR3cVhSQVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPNVN5VWRHWmdvT0ZNYUpzN2l2dmc4WDFMSVpuQTJub1JKNC12Z0hBLUtoMVhVZkN6bEFCQ0lQZEhxMEFuTDc1TlFCRHJmTTBiTFNyV3VyZUR6VGxybUNXN1phRURTeU04d2pLZUt2eE5KNVJOMVNhVFhwVm9ReXF4endXbVp4bDBGZ1Q2dElxMi0yeVRXWkc2VVV2OGpUNVhLaXluWDZzclAweVdGUVVNd3pWaW1RY1VzTlBsc2gxd3RheFFtNmI5Q05FY01qVEtCYzcxczI4OWYwNmJycHVv?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Joint U.S. Commercialization of RedHill's Talicia\u00ae Commences", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOUzZOaDZKQTFSQktQR3QtTTdXTUZ2S1lkcWs1ZXhJZFh1QlpzazB6ck5VRGJfRVFQdTBtLWNiMTNxbWsyNzI2aVdHX25tMGFkREJrNmU5S2NvQUxJUkRRYmRWa180SUs4X3lSdDlaMlY3NHBZZmpCRk51TG5VQXdJMl9tX255RWNEYlkzWlVRQkRTZFN1RnJsemZ2MTRMRzUtSW9UR3dfdl85TkxBb2JnUnhB?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redhill Biopharma stock soars on GLP-1 side effect treatment progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQUHl6anU4c0ZZN3FwZThtWURlT1h5ajI1am44c0NxOFpZbWRrRUVCelU4dGQ5Q0lvd1p6UkFkVlpQRkJwXzFvU3U0RWxRcG5QVVBtUnJuR25wMHRZS1g3V0dVWDhvenV2TURpdlFtamh4RzRuQ2xfekxMaXBudUExcjhvbnhnQ0t2N3hxMnVva0VoRmtXTG11VVlBZGh2MzUtR01sUlNwa2RRVFNVNVpfWUR3S0prMmk3NERzVnVwV183T0tUNzR6Rmxn?oc=5", "source_name": "Investing.com", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPcy1Oa25uZGRxd2JJNlRDaTllbnlZdUYyTjBPWXpRV01ETmVLbzJaM2QybWhDeWhtdDcwaC0xZTlqSmx0ZFZwZ1Fhbk0yM0p3aHVRSTVaWHFZM2RZU0MzRFBVaHc2V2E4ck5HY1lLX0R3aGNIbjZSLXNFVDB4NmN0TUlNbndIZUdOTkJWQ1JCX3RvVWttWVNHZ292RGxRclRvTjFrb3ZodHMxOFBYX29KdU5sdWpHcXhKbHJpZzhWTkkybmZLclh1eUF1Z3lBV1c5OUlVbGdYdGZkT2FBa3Bmc3l3NA?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's $1.8M Middle East Deal Signals Global Demand for Effective H. pylori Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNDFFSms4TkhWeTFHZTh0eHpxRlR3d2hTazFCV2J2Wi0teDVJQ01LVTViekNRTlRSMjc3b3NBSEVyMThYUTJieFBxcFcza3ZxM09Dam5MTFJXSzVyWVFOdjNnNldfejB4X00tc241WFhudkc5VW9TZEg4UE5iZzdhaWJCampIWGZtN3c0ZUQ0RUtaYWhvMzRiRXdOd1lxaENxaXhOUmxBX3dROVQwSVZlaG1odDUxajRO?oc=5", "source_name": "PharmTech.com", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOTHZ5ZzY1Skx2dXVRWTBmczRWaXpteU9nV0ZYd2xKRGJ3aXNGOUI3elZIR0xfRjdlcGIzVTk0cXBxTXlDRWhLUzNBd2E2SFlxejFuWDdpYXUxdE11MmJLSHQtSXpZc3ZKQ3VQTHdkaXdnc2JNZVZGQThyYzl6RVlHR1Jtal8xdmVZZXhQaUJBUmhBeVlWckczYUNQMGJiYmEyZzNNSVo1YTEzMUtxRTZGLVN4X25MOFJMRVVHaU9yWE5RNjM0QXBMd3VmdTBMYkRTZ2tZWW5fdHRTV2lXYllQSw?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-05T07:00:00+00:00", "published_display": "05 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOUEhDczdxWjZTYTBwYXZxaEtwVWdFdG1YWkZ1NDFqOWpkLU9JcEl1UmZDSFhib3F2Y05SbmlWTGY3djV0MFNQeUwwenV0MjdDdjNnQkZaMUJsVHB1MERNV2JWdEFiU19CX2hyVWpXRnhMQzNNS1BkZXA4N3h0TzlMYkhZUVF2dV9wWGhUWTQxQ3VDUE9Ea1ZXOURqLXA1U0p6Yk5ST19YVlF2ZzZxTlo2d2Z0YzdUTUNsQW5XUXA3MFhENnVOMHlTWkFubDlVSWdWYlFwTmtlZEpuQk8yNldlakF0bEYtXzlVMGRuejBR?oc=5", "source_name": "PR Newswire", "published_at": "2024-10-14T07:00:00+00:00", "published_display": "14 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RedHill's Talicia\u00ae Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdXpoLVE3VWR0SVk1X0tfRkZ1RTFvckR0YjlsYm1XUjBHRll4ekVsSVJubFYxU05TSm40R1lzMWcxa203Vzg1LXBudmhKT3J1VFFxVlBKNjBLVDBYSjRmTG4ycWJPSGhvZnpzWm95QjVBTEotbWlxaGlzakdDdUp4Zjh5SW5OZjRCRndqSWVwODF2eUFCbnlEbDJ4bkZoaG41cHRxYVZfbzZuRWRzZk9lNzBjb2lkM0hzWXBwcW5uTE4?oc=5", "source_name": "Stock Titan", "published_at": "2024-09-09T07:00:00+00:00", "published_display": "09 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Redhill Biopharma (RDHL) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOeldnLURLZDg0YVJRWGlYdUJRYWFYanQ3YnBUOS1mTktnM1o4bGxVOFQyUThwamJycnZTS0gyMnhtMHpFd29hQ2Q2NE80cTNvU21KUUx1RUxPbmxCaF9TandHbGRoUEVfVDhjaXc4NVlKNWJPZ2cxa3kza0xJLWVsQw?oc=5", "source_name": "MarketBeat", "published_at": "2020-04-30T03:00:09+00:00", "published_display": "30 Apr 2020 03:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RDHL Stock Price and Chart \u2014 NASDAQ:RDHL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5QOGctMGxneEZxZzhlblctX0ZoUlN2UlJwazE4cVBhc2R0T0liUFpRWkYxRll2UzBkMHBRdC04bXFQZHd0TXFFMGh0RFFiaVVjb095Mnc3MGExb1Z0?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:06:25+00:00", "published_display": "21 Jul 2017 03:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 69, "total_relevant": 42, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 23, "score": 57, "total": 42, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 0.81, "latest_week": "2026-06-12", "one_week_move": -21.4, "four_week_move": -21.4, "twelve_week_move": -7.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.30305, "market_dynamics_buy_signal": false, "relative_strength": -46.623042, "fair_value_gap": -90.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.6081, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-21.4% over one week, -21.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingKey", "count": 7}, {"label": "PR Newswire", "count": 7}, {"label": "Investing.com", "count": 3}, {"label": "Sahm", "count": 2}, {"label": "grafa.com", "count": 2}, {"label": "GuruFocus", "count": 1}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Regulatory and legal", "count": 6}, {"label": "Earnings", "count": 4}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-21.4% over one week, -21.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Redhill Biopharma Ltd (RDHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution"}], "updated_at": "2026-06-19T14:53:02.293635+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}